Safety, tolerability, pharmacokinetic, pharmacodynamic and immunogenicity profiles of Exendin-4-IgG4-Fc in healthy subjects: A phase 1, single-centre, randomized, double-blind, dose escalation study.
Chen GL, Liu Y, Gao XF, Wu KQ, Yang YK, Chen Y, Peng CG, Jin TH, Huang YB, Zhang YW, Su J, Jiang Q, Guo T, Zhao J, Peng XN, Peng JY, Li SX, Sun YL, Zhang HM, Fu YL, Luo D, Ma Y, Shen ZW, Zhang YT, Shou ZF.
Chen GL, et al. Among authors: su j.
Diabetes Obes Metab. 2024 Apr;26(4):1395-1406. doi: 10.1111/dom.15441. Epub 2024 Jan 29.
Diabetes Obes Metab. 2024.
PMID: 38287130
Clinical Trial.